Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
JAMA Cardiol. 2020 Dec 1;5(12):1349-1357. doi: 10.1001/jamacardio.2020.3638.
Medicare Advantage (MA), a private insurance plan option, now covers one-third of all Medicare beneficiaries. Although patients with cardiovascular disease enrolled in MA have been reported to receive higher quality of care in the ambulatory setting than patients enrolled in fee-for-service (FFS) Medicare, it is unclear whether MA is associated with higher quality in patients hospitalized with heart failure, or alternatively, if incentives to reduce utilization under MA plans may be associated with worse care.
To determine whether there are differences in quality of care received and in-hospital outcomes among patients enrolled in MA vs FFS Medicare.
DESIGN, SETTING, AND PARTICIPANTS: Observational, retrospective cohort study of patients hospitalized with heart failure in hospitals participating in the Get With the Guidelines-Heart Failure registry.
Medicare Advantage enrollment.
In-hospital mortality, discharge disposition, length of stay, and 4 heart failure achievement measures.
Of 262 626 patients hospitalized with heart failure, 93 549 (35.6%) were enrolled in MA and 169 077 (64.4%) in FFS Medicare. The median (interquartile range) age was 78 (70-85) years for patients enrolled in MA and 78 (69-86) years for patients enrolled in FFS Medicare. Standard mean differences in age, sex, prevalence of comorbidities, or objective measures on admission, including vital signs and laboratory values, were less than 10%. After adjustment, there were no statistically significant differences in receipt of evidence-based β-blockers when indicated; angiotensin-converting enzyme inhibitor, angiotensin II receptor blockers, or angiotensin receptor-neprilysin inhibitors at discharge; measurement of left ventricular function; and postdischarge appointments by Medicare insurance type. Patients enrolled in MA, however, had higher odds of being discharged directly home (adjusted odds ratio [AOR], 1.16; 95% CI, 1.13-1.19; P < .001) relative to patients enrolled in FFS Medicare and lower odds of being discharged within 4 days (AOR, 0.97; 95% CI, 0.93-1.00; P = .04). There was no significant difference in in-hospital mortality between patients with MA and patients with FFS Medicare (AOR, 0.98; 95% CI, 0.92-1.03; P = .42).
Among patients hospitalized with heart failure, no observable benefit was noted in quality of care or in-hospital mortality between those enrolled in MA vs FFS Medicare, except lower use of post-acute care facilities. As MA continues to grow, it will be important to ensure that participating private plans provide an added value to the patients they cover to justify the higher administrative costs compared with traditional FFS Medicare.
医疗保险优势(MA)是一种私人保险计划选择,现在覆盖了三分之一的所有医疗保险受益人。尽管在门诊环境中,与参加传统付费服务(FFS)医疗保险的患者相比,参加 MA 的心血管疾病患者的护理质量更高,但尚不清楚 MA 是否与心力衰竭住院患者的更高质量有关,或者 MA 计划减少使用的激励措施是否与护理质量更差有关。
确定参加 MA 与参加 FFS 医疗保险的患者在护理质量和住院结果方面是否存在差异。
设计、地点和参与者:在参加 Get With the Guidelines-Heart Failure 登记处的住院心力衰竭患者中进行观察性、回顾性队列研究。
医疗保险优势的参与。
住院心力衰竭患者的院内死亡率、出院去向、住院时间和 4 项心力衰竭达标措施。
在 262626 名住院心力衰竭患者中,93549 名(35.6%)参加了 MA,169077 名(64.4%)参加了 FFS 医疗保险。参加 MA 的患者的中位(四分位间距)年龄为 78(70-85)岁,参加 FFS 医疗保险的患者为 78(69-86)岁。年龄、性别、合并症的患病率或入院时的客观指标(包括生命体征和实验室值)的标准均数差异小于 10%。调整后,在需要时接受基于证据的β受体阻滞剂、出院时使用血管紧张素转换酶抑制剂、血管紧张素 II 受体阻滞剂或血管紧张素受体脑啡肽酶抑制剂、左心室功能测量以及根据医疗保险类型进行的出院后预约方面,两种医疗保险类型的患者之间没有统计学上显著的差异。然而,与参加 FFS 医疗保险的患者相比,参加 MA 的患者更有可能直接出院回家(调整后的优势比 [OR],1.16;95%CI,1.13-1.19;P<0.001),而在 4 天内出院的可能性较低(OR,0.97;95%CI,0.93-1.00;P=0.04)。参加 MA 的患者与参加 FFS 医疗保险的患者在院内死亡率方面无显著差异(OR,0.98;95%CI,0.92-1.03;P=0.42)。
在心力衰竭住院患者中,与参加 FFS 医疗保险的患者相比,参加 MA 的患者在护理质量或院内死亡率方面没有明显获益,除了急性后护理设施的使用率较低。随着 MA 的持续增长,确保参与的私人计划为他们所覆盖的患者提供附加价值以证明与传统 FFS 医疗保险相比更高的管理成本是很重要的。